Acción SNNAQ SIENNA BIOPHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Sienna Biopharmaceuticals, Inc.

Acciones

SNNAQ

US82622H1086

Diferido OTC Markets
Otros sitios de cotización
 18:16:25 10/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,000001 USD -.--% Gráfico intradía de Sienna Biopharmaceuticals, Inc. -.--% -.--%
2019 Transcript : Sienna Biopharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03:55 PM
2019 Transcript : Sienna Biopharmaceuticals, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-09-2019 11:00 AM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.
SIENNA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SNNAQ
  4. Noticias Sienna Biopharmaceuticals, Inc.
  5. Otros idiomas